Fig. 2: Validation of ZRSR2 overexpression in PDX and patient CRPC tissues. | Prostate Cancer and Prostatic Diseases

Fig. 2: Validation of ZRSR2 overexpression in PDX and patient CRPC tissues.

From: ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development

Fig. 2

a qRT-PCR was used to determine the expression of ZRSR2 in multiple PDX lines after host castration. The results are presented as means ± SEM. p values for each sample were determined based on paired parental tumors (*p < 0.05; **p < 0.01; ***p < 0.001). b ZRSR2 protein expressions in LTL-313H tumor tissues at HNPC, 12 weeks after castration, and after CRPC development were determined by western blotting. c, d, e ZRSR2 mRNA expressions in benign prostate tissue, HNPC tissue, and CRPC tissue from three independent clinical cohorts. The vertical scatter plots show means ± SD. f Kaplan–Meier plots indicating disease-free survival times of PCa patients grouped according to ZRSR2 expression. Significance between the groups was analyzed by the log-rank test.

Back to article page